Impaired kidney function was also identified as a key risk factor for heart disease, contributing to about 12% of global ...

The daily living and mobility components will be under review, but there are no plans to means-test the benefit.

Chronic Kidney Disease affects 14% of adults and caused 1.5M deaths in 2023—a 6% rise since 1993. Often underdiagnosed, it drives heart disease and disability. Experts call for early detection, access ...

The seven-mile stretch of coast between Cape Arago and Sunset Bay contains enough natural wonders to fill years of exploration, from secluded beaches to prime wildlife viewing areas where sea lions, ...

Earlier today, Hyperfine, Inc. released financial results for the quarter ended September 30, 2025. Before we begin, I would ...

Thank you, Paul. The continued momentum in both our U.S. and international businesses during Q3 saw over 14 million average ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced that data from multiple pipeline programs, including long-term and safety results ...

The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets), currently under investigation for first-line use in ...

The recent improved sanitary, nutritional, and socioeconomic conditions have led to an increase in life expectancy, making ...

Background Pain and fatigue are among the most debilitating symptoms of systemic sclerosis (SSc), severely impairing quality ...

Interstitial lung diseases (ILD) are a heterogeneous group of chronic disorders leading to progressive lung damage and ...